SCHEMBL24709131

SCHEMBL24709131

O=c1n(CCCCc2ccccc2)c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 5/20 0.76
CACNA1H O95180 5/20 0.76
HTR2A P28223 5/20 0.61
SLC6A3 Q01959 4/20 0.61
CACNA1F O60840 3/20 0.61
DRD4 P21917 3/20 0.61
HRH2 P25021 3/20 0.61
ADRA1A P35348 3/20 0.61
HRH1 P35367 3/20 0.61
OPRM1 P35372 3/20 0.61
DRD3 P35462 3/20 0.61
OPRD1 P41143 3/20 0.61
OPRK1 P41145 3/20 0.61
HTR6 P50406 3/20 0.61
CACNA1D Q01668 3/20 0.61
CACNA1S Q13698 3/20 0.61
CACNA1C Q13936 3/20 0.61
DRD1 P21728 2/20 0.61
HTR2C P28335 2/20 0.61
KDM4E B2RXH2 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079786 1.00 CACNA1G (0.76) CACNA1GCACNA1HHTR2ASLC6A3CACNA1F
SCHEMBL24708799 0.93 CACNA1G (0.84) CACNA1GCACNA1HHTR2ASLC6A3CACNA1F
SCHEMBL31000433 0.93 CACNA1G (0.84) CACNA1GCACNA1HHTR2ASLC6A3CACNA1F
SCHEMBL31000439 0.91 CACNA1G (0.87) CACNA1GCACNA1HHTR2ADRD4DRD3
SCHEMBL24708743 0.91 CACNA1G (0.87) CACNA1GCACNA1HHTR2ADRD4DRD3
SCHEMBL24708750 0.91 CACNA1G (0.87) CACNA1GCACNA1HHTR2ADRD4DRD3
SCHEMBL24709111 0.89 CACNA1G (0.83) CACNA1GCACNA1HHTR2ADRD3KDM4E
SCHEMBL30079694 0.87 CACNA1G (1.00) CACNA1GCACNA1HDRD4OPRM1DRD3
SCHEMBL24708724 0.87 CACNA1G (1.00) CACNA1GCACNA1HDRD4OPRM1DRD3
SCHEMBL10281563 0.87 OPRM1 (0.65) CACNA1GCACNA1HHTR2ASLC6A3CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287019-A1 T-TYPE CALCIUM CHANNEL BLOCKER FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2024-08-29 US disclosed
EP-4353713-A1 T-TYPE CALCIUM CHANNEL BLOCKER Kinki University (JP) 2024-04-17 EP disclosed
WO-2022260016-A1 T-TYPE CALCIUM CHANNEL BLOCKER 学校法人近畿大学 2022-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287019-A1 T-TYPE CALCIUM CHANNEL BLOCKER CACNA1G, CACNA1I, CACNA1H CACNA1G 1/4885CACNA1H 3/4885HTR2A 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.